Accelerate Circular RNA, Self-Amplifying RNA and Transfer RNA into Safe and Effective Clinical Candidates with Therapeutic Potentials Across All Diseases by Overcoming Quality, Stability, Delivery & Large-Scale Manufacturing Hurdles

May, 7-9, 2024 | Boston, MA

Welcome to the 3rd Next Generation RNA Therapeutics Summit

Pioneering the Next Breakthrough in Durable & Potent Circular RNA, Transfer RNA, Self-Amplifying RNA Therapeutics for Patients in Need

As the field celebrates the world’s first self-amplifying mRNA vaccine approval from CSL and Arcturus Therapeutics, and huge investments such as the $270 million raised by Orbital Therapeutics, the field of next generation RNA therapeutics emerges as a preferred RNA platform, with circular RNA, self-amplifying RNA and transfer RNA offering potential for improved stability, longevity, and increased therapeutic potential.

The 3rd Next Generation RNA Therapeutics Summit returns to Boston to cover the depth and breadth of circular RNA, self-amplifying RNA (saRNA) and transfer RNA, from discovery to clinic and towards scalable manufacturing, equipping RNA leaders with strategic insights to fast-track these therapies into the clinic unlocking the huge therapeutic and commercial potential of this emerging class of medicines.

FULL AGENDA

Full Event Guide 3rd Next Generation RNA Therapeutics

Hear first-hand from the leading minds of the field, including representatives from Replicate Bioscience, Sail Biomedicines, Johnson & Johnson, Pfizer, Orbital Therapeutics, and more to accelerate discovery, development, and manufacturing of safe and effective next generation RNA therapeutics with significant advantages over the traditional therapies to treat previously “incurable” diseases with unmet needs.

A Snapshot of the 22+ World-Class Speaker Faculty:

Why Attend?

2

Investigate the most recent advancements and technologies in Self-Amplifying RNA therapeutics, focusing on enhancing manufacturing and analysis capabilities to elevate patient treatment outcomes and produce successful RNA medicines with high quality, traceability, & reliability with case studies from Replicate Bioscience, Johnson & Johnson, and Strand Therapeutics

4

Explore the latest research findings on circular RNA and pinpoint the primary hurdles including improving yield, purity, and scalability in the manufacturing and analytics of circular RNA to increase clinical success of circular RNAs towards patients with invaluable insights from industry leaders at Orbital Therapeutics, Sail Biomedicines, & NoctuRNA Therapeutics

6

Unlock the widespread potential of circular RNA, transfer RNA and self-amplifying RNA therapeutics with improved sequence design, target selection and in vivo delivery to treat previously “incurable” diseases with unmet needs with insights from Atomic AI & Sanofi

8

Address the importance of collaboration and investment in advancing pharma and biotech innovations, and discuss the strategies for mitigating risks and maximizing returns on investment with investor insights from Rothwell Figg as well as John Hopkins University & Capstan Therapeutics

10

Engage in an in-depth discussion regarding the ongoing immunogenicity studies aimed at mitigating off-target effects and evaluating the safety and efficacy of your of circular RNA, transfer RNA and self-amplifying RNA therapeutics. Explore the different strategies to ensure the optimal performance and safety profile of cutting-edge RNA with insights from Pfizer & Sanofi

Who Attends This Meeting?

Companies Attending 3rd Next Generation RNA Therapeutics

Other Events in the World RNA Series